Mouse Anti-MERS-CoV S Recombinant Antibody (clone 4C2) (CAT#: PABL-324)

Figure 1 Interference of the spike/hCD26 interaction by the antibodies.

hCD26 was transiently expressed in BHK21 cells and tested by flow cytometry for MERS-RBD binding with or without the antibodies. Left to right: no antibody, with 2H8 (a non-neutralizing antibody targeting MERS-RBD), with 2E6, with 4C2.

Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J.,... & Zhang, B. (2015). A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.Cell research, 25(11), 1237.

Figure 2 In vitro neutralization tests using the pseudotyped and the live viruses.

The non-neutralizing antibody 2H8 or an irrelevant antibody L2 was used as the negative controls. Neutralization of the pseudoviruses by the antibodies (D). Neutralization of the live viruses by the antibodies (E).

Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J.,... & Zhang, B. (2015). A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.Cell research, 25(11), 1237.

Figure 3 Humanized 4C2 (4C2h) sustains similar neutralizing activity and biochemical characters to 4C2.

(A) SPR analysis of the MERS-RBD binding to 4C2h. The kinetic profile is shown. (B) Flow cytometric assay showing the blocking by 4C2h of the binding between MERS-RBD and hCD26 on the cell surface. (C, D) In vitro neutralization tests of 4C2h using the pseudotyped (C) and the live (D) viruses. The non-neutralizing antibody 2H8 or an irrelevant antibody L2 was used as the negative controls. The data are from four independent experiments, and mean ± SD is presented. (E, F) Protective efficacies of 4C2h in vivo. Ad5-hCD26-transduced BALB/c mice were treated intravenously with a single dose of antibody one day before (E) or after (F) the MERS-CoV challenge. Virus titers in the lungs were measured at 3 and 5 dpi and are expressed as PFUs per gram of lung tissue.

Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J.,... & Zhang, B. (2015). A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.Cell research, 25(11), 1237.